This study is currently recruiting participants.
Number
000194-C
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 18 Years Max Age: 120 Years
Referral Letter Required
No
Population Exclusion(s)
Fetuses;Pregnant Women;Children
Keywords
Pancreatic Ductal Adenocarcinoma; pegylated peptide drug; Apoptosis; Endothelial Cells; Angiogenesis
Recruitment Keyword(s)
None
Condition(s)
Pancreatic Cancer; Solid Tumors
Investigational Drug(s)
ProAgio (ACT-50)
Investigational Device(s)
Intervention(s)
Drug: ProAgio Drug: Gemcitabine
Supporting Site
National Cancer Institute
Pancreatic cancer is the third most common cause of cancer death in the United States. People are usually diagnosed at an advanced stage. But even those with early stage disease have a poor prognosis. Researchers want to see if a new drug can help.
Objective:
To find the safest dose of ProAgio to treat advanced pancreatic and other types of cancer.
Eligibility:
People ages 18 and older with a solid tumor that is not curable with available standard therapies.
Design:
Participants will be screened with a medical record review and physical exam. They will have blood and urine tests. They will have an electrocardiogram to test heart function. They may have imaging scans and/or bone scans. For these, they may have a contrast agent injected into their arm.
Treatment will be given in 14-day cycles. Participants will receive ProAgio as 30-minute intravenous injections once every cycle. They may be given medicine for side effects. For the first 3 cycles, they will be admitted to the NIH Clinical Center for at least 48 hours. They may receive ProAgio until their disease gets worse, they have serious side effects, or they decide to stop treatment.
Participant will have several study visits. At these visits, they will repeat some screening tests. They will have imaging scans every 3 cycles starting with cycle 4. They may have a tumor biopsy.
About 4 weeks after treatment ends, participants will have a safety visit. Then they will be contacted every 3 months by phone for 1 year.
--Back to Top--
INCLUSION CRITERIA For the escalation cohort: -Histologic or cytologic diagnosis of a solid tumor malignancy for which no curative therapy exists. -Individuals must have evaluable disease, either by clinical exam, biochemical markers (including but not limited to CA 19-9 serum tumor marker for pancreatobiliary cancer, or other appropriate tumor marker in other tumor types), and/or radiographic studies. -Individuals must have received at least one prior systemic treatment for advanced disease. For the expansion cohort: -Histologic or cytologic diagnosis of non-neuroendocrine pancreatic cancer. Individuals with mixed acinar-neuroendocrine histology are eligible. -All individuals must have measurable disease, per RECIST 1.1. -All individuals must have advanced or recurrent disease and have received at least one prior systemic treatment. Specifically: --Individuals with metastatic, locally advanced/unresectable, or borderline resectable pancreatic cancer at diagnosis, must have received at least one prior systemic treatment and still be considered ineligible for potentially curative resection. --Individuals who have undergone surgical resection and have tumor recurrence that is not amenable to local therapy, are eligible if: ---Tumor recurs within six months of the completion of adjuvant therapy, OR ---Further standard of care therapy is not a viable option due to prior resistance or intolerance, or a medical contraindication to both FOLFIRINOX (or NALIRIFOX) and gemcitabine-based chemotherapy -Individuals in the Biopsy Arm of the expansion cohort must have disease amenable to safe biopsy and willingness to undergo the procedure. -All individuals must be more than 14 days removed from most recent standard of care or experimental drug treatment for their tumor. -Age >18 years. Because no dosing or adverse event data are currently available on the use of ProAgio in individuals <18 years of age, children are excluded from this study. -ECOG performance status <=2 (Karnofsky >= 60%) -Individuals must have adequate organ and marrow function as defined below: --Absolute neutrophil count (ANC) >=1,000/mcL --Hemoglobin (hgb) >=9 g/dL --Platelets >=75,000/mcL --Aspartate aminotransferase (AST)/alanine transaminase (ALT) (<= 2.5 x institutional upper limit of normal (ULN). AST and ALT (up to 5x ULN) is permitted for individuals with liver metastases) --Total bilirubin <=1.5 X institutional ULN --Creatinine within normal institutional limits OR --creatinine clearance >=60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal --Serum albumin >2.5 mg/dL without intravenous supplementation -Individuals must have: --Baseline QTcF interval of <= 470 ms --Baseline resting heart rate > 45 beats and <100 beats per minute -Individuals of child-bearing potential (IOCBP) and individuals able to father a child must agree to use an effective method of contraception as follows: --IOCBP must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after the last dose of study drug(s). --Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 6 months after the last dose of the study drug(s). We also will recommend individuals able to father a child with IOCBP partners to ask them to be on an effective birth control (hormonal, intrauterine device [IUD], surgical sterilization. - Ability of individual to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA -Diagnosis of primary malignant central nervous system (CNS) tumor. -Individuals who are receiving any other investigational agents. -Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including but not limited to significant pulmonary disease other than that related to the primary cancer, uncontrolled diabetes mellitus, unstable angina, significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease) and/or psychiatric illness/social situations within 12 weeks that would limit compliance with study requirements. -Individuals with known diagnosis of a chronic neurologic disorders (such as multiple sclerosis, Huntington s disease, Parkinson s disease, or uncontrolled epilepsy) which causes motor disturbance, visual disturbance or seizure and could confound assessment of neurologic toxicity caused by the study drug. -Pregnant or nursing individuals are excluded from this study because the study drug(s) are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drug(s), nursing should be discontinued if the mother is treated with the study drug(s). -Individuals with leptominengeal disease or with CNS metastases that are untreated, have required steroid treatment within the last 4 weeks, or anti-convulsant therapy in the last 14 days. For dose escalation cohort only: Individuals with any known CNS metastases are excluded. Those with symptoms suggestive of possible CNS metastases (such as new headaches) must undergo brain MRI as part of screening. -Individuals who have undergone a recent minor surgical procedure (within <=14 days) such as biliary stenting or major surgical procedure (within <= 28 days). -Individuals who have undergone recent (within <=14 days) external beam radiation therapy and who have undergone recent (within <= 28 days) treatment with radioactive therapeutics (such as Y90 or radio-immune conjugates). -Individuals with uncontrolled bleeding episodes <= 28 days prior to enrollment. -Individuals with active or uncontrolled infections. -Individuals with human immunodeficiency virus (HIV) and detectable viral load (VL). Individuals on appropriate highly active anti-retroviral therapy (AART) with undetectable VL are eligible. -Individuals with a history of Hepatitis B (HBV) or Hepatitis C (HCV) are excluded unless there is documented evidence of effective treatment and/or cure with undetectable VL. -Individuals with recent (within <= 28 days) thromboembolic disease including but not limited to acute coronary syndrome, stroke, or transient ischemic attack, recent deep vein thrombosis or pulmonary embolism. -Individuals with thromboembolic disease including but not limited to acute coronary syndrome, stroke, or transient ischemic attack, recent deep vein thrombosis or pulmonary embolism who have continued symptoms, or who are not on stable doses of appropriate antiplatelet/anticoagulant regimens.
For the escalation cohort:
-Histologic or cytologic diagnosis of a solid tumor malignancy for which no curative therapy exists.
-Individuals must have evaluable disease, either by clinical exam, biochemical markers (including but not limited to CA 19-9 serum tumor marker for pancreatobiliary cancer, or other appropriate tumor marker in other tumor types), and/or radiographic studies.
-Individuals must have received at least one prior systemic treatment for advanced disease.
For the expansion cohort:
-Histologic or cytologic diagnosis of non-neuroendocrine pancreatic cancer. Individuals with mixed acinar-neuroendocrine histology are eligible.
-All individuals must have measurable disease, per RECIST 1.1.
-All individuals must have advanced or recurrent disease and have received at least one prior systemic treatment. Specifically:
--Individuals with metastatic, locally advanced/unresectable, or borderline resectable pancreatic cancer at diagnosis, must have received at least one prior systemic treatment and still be considered ineligible for potentially curative resection.
--Individuals who have undergone surgical resection and have tumor recurrence that is not amenable to local therapy, are eligible if:
---Tumor recurs within six months of the completion of adjuvant therapy, OR
---Further standard of care therapy is not a viable option due to prior resistance or intolerance, or a medical contraindication to both FOLFIRINOX (or NALIRIFOX) and gemcitabine-based chemotherapy
-Individuals in the Biopsy Arm of the expansion cohort must have disease amenable to safe biopsy and willingness to undergo the procedure.
-All individuals must be more than 14 days removed from most recent standard of care or experimental drug treatment for their tumor.
-Age >18 years. Because no dosing or adverse event data are currently available on the use of ProAgio in individuals <18 years of age, children are excluded from this study.
-ECOG performance status <=2 (Karnofsky >= 60%)
-Individuals must have adequate organ and marrow function as defined below:
--Absolute neutrophil count (ANC) >=1,000/mcL
--Hemoglobin (hgb) >=9 g/dL
--Platelets >=75,000/mcL
--Aspartate aminotransferase (AST)/alanine transaminase (ALT) (<= 2.5 x institutional upper limit of normal (ULN). AST and ALT (up to 5x ULN) is permitted for individuals with liver metastases)
--Total bilirubin <=1.5 X institutional ULN
--Creatinine within normal institutional limits
OR
--creatinine clearance >=60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal
--Serum albumin >2.5 mg/dL without intravenous supplementation
-Individuals must have:
--Baseline QTcF interval of <= 470 ms
--Baseline resting heart rate > 45 beats and <100 beats per minute
-Individuals of child-bearing potential (IOCBP) and individuals able to father a child must agree to use an effective method of contraception as follows:
--IOCBP must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after the last dose of study drug(s).
--Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 6 months after the last dose of the study drug(s). We also will recommend individuals able to father a child with IOCBP partners to ask them to be on an effective birth control (hormonal, intrauterine device [IUD], surgical sterilization.
- Ability of individual to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA
-Diagnosis of primary malignant central nervous system (CNS) tumor.
-Individuals who are receiving any other investigational agents.
-Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including but not limited to significant pulmonary disease other than that related to the primary cancer, uncontrolled diabetes mellitus, unstable angina, significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease) and/or psychiatric illness/social situations within 12 weeks that would limit compliance with study requirements.
-Individuals with known diagnosis of a chronic neurologic disorders (such as multiple sclerosis, Huntington s disease, Parkinson s disease, or uncontrolled epilepsy) which causes motor disturbance, visual disturbance or seizure and could confound assessment of neurologic toxicity caused by the study drug.
-Pregnant or nursing individuals are excluded from this study because the study drug(s) are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drug(s), nursing should be discontinued if the mother is treated with the study drug(s).
-Individuals with leptominengeal disease or with CNS metastases that are untreated, have required steroid treatment within the last 4 weeks, or anti-convulsant therapy in the last 14 days. For dose escalation cohort only: Individuals with any known CNS metastases are excluded. Those with symptoms suggestive of possible CNS metastases (such as new headaches) must undergo brain MRI as part of screening.
-Individuals who have undergone a recent minor surgical procedure (within <=14 days) such as biliary stenting or major surgical procedure (within <= 28 days).
-Individuals who have undergone recent (within <=14 days) external beam radiation therapy and who have undergone recent (within <= 28 days) treatment with radioactive therapeutics (such as Y90 or radio-immune conjugates).
-Individuals with uncontrolled bleeding episodes <= 28 days prior to enrollment.
-Individuals with active or uncontrolled infections.
-Individuals with human immunodeficiency virus (HIV) and detectable viral load (VL). Individuals on appropriate highly active anti-retroviral therapy (AART) with undetectable VL are eligible.
-Individuals with a history of Hepatitis B (HBV) or Hepatitis C (HCV) are excluded unless there is documented evidence of effective treatment and/or cure with undetectable VL.
-Individuals with recent (within <= 28 days) thromboembolic disease including but not limited to acute coronary syndrome, stroke, or transient ischemic attack, recent deep vein thrombosis or pulmonary embolism.
-Individuals with thromboembolic disease including but not limited to acute coronary syndrome, stroke, or transient ischemic attack, recent deep vein thrombosis or pulmonary embolism who have continued symptoms, or who are not on stable doses of appropriate antiplatelet/anticoagulant regimens.
Principal Investigator
Referral Contact
For more information: